All lobbying filings

HARBINGER STRATEGIES, LLC

HARBINGER STRATEGIES, LLC filed a Q3 report for GENENTECH, INC. on October 21, 2026, reporting $60,000 in lobbying income.

Lobbying for GENENTECH, INC. · Biotech company developing medicines to treat patients.

All filings by HARBINGER STRATEGIES, LLC · Everything GENENTECH, INC. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 21, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

California

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Taxation/Internal Revenue Code

Issues related to corporate taxation including corporate rate; deductibility of research and development expenses; and international taxation (Foreign Derived Intangible Income). P.L. 119-21.

Health Issues

Issues related to drug pricing. Issues related to the 340B Drug Discount Program.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.